Investigator-initiated Trials (IITs) are an integral and increasingly
important part of the clinical research landscape. In this article, John
Denier at Clinigen discusses the potential benefits of utilising an
outsourced or customised service designed to meet the unique drug
supply needs associated with IIT programmes.